- Home
- TKNO vs NGNE Comparison
TKNO vs NGNE Comparison
Compare TKNO & NGNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TKNO
- NGNE
- Stock Information
- Founded
- TKNO 1996
- NGNE 2003
- Country
- TKNO United States
- NGNE United States
- Employees
- TKNO N/A
- NGNE N/A
- Industry
- TKNO Medicinal Chemicals and Botanical Products
- NGNE Biotechnology: Pharmaceutical Preparations
- Sector
- TKNO Health Care
- NGNE Health Care
- Exchange
- TKNO Nasdaq
- NGNE Nasdaq
- Market Cap
- TKNO 356.4M
- NGNE 325.3M
- IPO Year
- TKNO 2021
- NGNE N/A
- Fundamental
- Price
- TKNO $4.34
- NGNE $21.74
- Analyst Decision
- TKNO
- NGNE Strong Buy
- Analyst Count
- TKNO 0
- NGNE 7
- Target Price
- TKNO N/A
- NGNE $41.86
- AVG Volume (30 Days)
- TKNO 318.0K
- NGNE 122.9K
- Earning Date
- TKNO 08-07-2025
- NGNE 08-12-2025
- Dividend Yield
- TKNO N/A
- NGNE N/A
- EPS Growth
- TKNO N/A
- NGNE N/A
- EPS
- TKNO N/A
- NGNE N/A
- Revenue
- TKNO $38,250,000.00
- NGNE $925,000.00
- Revenue This Year
- TKNO $8.73
- NGNE N/A
- Revenue Next Year
- TKNO $16.53
- NGNE N/A
- P/E Ratio
- TKNO N/A
- NGNE N/A
- Revenue Growth
- TKNO 3.79
- NGNE N/A
- 52 Week Low
- TKNO $3.34
- NGNE $6.88
- 52 Week High
- TKNO $10.37
- NGNE $74.49
- Technical
- Relative Strength Index (RSI)
- TKNO 36.34
- NGNE 54.39
- Support Level
- TKNO $5.03
- NGNE $21.16
- Resistance Level
- TKNO $5.31
- NGNE $23.80
- Average True Range (ATR)
- TKNO 0.35
- NGNE 1.52
- MACD
- TKNO 0.01
- NGNE -0.18
- Stochastic Oscillator
- TKNO 15.75
- NGNE 33.59
About TKNO Alpha Teknova Inc.
Alpha Teknova Inc provides critical reagents that enable the discovery, development, and production of biopharmaceutical products such as drug therapies, novel vaccines, and molecular diagnostics. Its offer three product types: pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It derives key revenue from United States.
About NGNE Neurogene Inc.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.